Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 2.1
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutra
Data is available to registered users only
Target Price
The average target price of ALDVI.PA is 3.3 and suggests 58% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Data is available to registered users only
Buy
Sell